ARP 4922
Alternative Names: ARP-4922Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Arpeggio Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action NF-E2-related factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 07 Aug 2024 Preclinical trials in Non-small cell lung cancer in USA (PO) before August 2024 (Arpeggio Biosciences pipeline, August 2024)
- 07 Aug 2024 Pharmacodynamics data from preclinical studies in Non small cell lung cancer released by Arpeggio Biosciences (Arpeggio Biosciences pipeline, August 2024)